Biomedical subjects

T W Huizinga

Publications and source records attributed to T W Huizinga.

85 records · Page 5Linked to original sources

PubMed1990

Reactivity of cloned, expressed human Fc gamma RIII isoforms with monoclonal antibodies which distinguish cell-type-specific and allelic forms of Fc gamma RIII.

We have isolated and expressed a cDNA encoding human NK cell Fc gamma RIII. The NK cell cDNA differs from the neutrophil Fc gamma RIII cDNA by a number of point mutations and encodes an additional 21 amino acids at its C-terminus. When transiently expressed neutrophil and NK cell Fc gamma RIII were digested with N-glycanase, deglycosylated neutrophil Fc gamma RIII had a more rapid electrophoretic mobility than NK cell Fc gamma RIII, as is observed for the human Fc gamma RIII isoforms on normal cells. The neutrophil and NK cell Fc gamma RIII isoforms apparently result from cell-type specific expression of different forms of Fc gamma RIII mRNA. A TaqI RFLP was also found for human Fc gamma RIII. Monoclonal antibodies which have been used to distinguish the neutrophil and NK cell Fc gamma RIII isoforms and the NA1 and NA2 alleles of human neutrophil Fc gamma RIII were employed to study the expression of two Fc gamma RIII cDNA clones derived from neutrophils and NK cells. Fc gamma RIII encoded by the neutrophil-derived cDNA reacts with the monoclonal antibody CLBgran11, while the NK-cell Fc gamma RIII cDNA expresses the Fc receptor which carries an antigenic determinant recognized by the antibody GRM1. Characterization of hybrid Fc gamma RIII constructed by interchange of restriction fragments between the neutrophil and NK cell cDNAs allowed localization of antigenic determinants recognized by the monoclonal antibodies.

Alleles↗

PubMed1990

Cross-linking of both types of IgG Fc receptors, Fc gamma RI and Fc gamma RII, enhances intracellular free Ca2+ in the monocytic cell line U937.

We have studied the effects of Fc receptor triggering on the free cytosolic Ca2+ concentration, [Ca2+]i, in U937. These cells express two types of IgG Fc receptors, Fc gamma RI and Fc gamma RII. Binding of several anti-Fc gamma RI and anti-Fc gamma RII mouse monoclonal antibodies (MoAb) to Quin2- or Indo-1-loaded U937 cells had no direct effect on [Ca2+]i. After addition of a bridging anti-mouse Ig antibody however, transient increases in [Ca2+]i were observed for both types of Fc gamma R. One of the anti-Fc gamma RII MoAb, CIKM5, was exceptional in that it could induce Ca2+ increases in U937 cells by itself. Studies with F(ab')2 fragments of CIKM5 revealed that this MoAb simultaneously binds to Fc gamma RII, via both its Fab and Fc fragments, which might induce cross-linking of two Fc gamma RII molecules. One anti-Fc gamma RI MoAb, 197, a mouse (m)IgG2a antibody directed to an epitope outside the IgG-binding region, remarkably also caused an immediate increase in [Ca2+]i, but only when added to U937 precultured with gamma interferon (IFN-gamma). Fc gamma RI can bind monomeric human IgG as well as mIgG2a, and cross-linking of cytophilic Ig induced an increase in [Ca2+]i. Our results show that [Ca2+]i increases can be induced only after cross-linking of Fc gamma R, either via anti-Fc gamma R MoAb or via Fc-FcR interactions. Furthermore, we show that Fc gamma R cross-linking results in activation of the Ca2+/phosphatidylinositol (PI) signal transduction pathway.

Aminoquinolines↗

PubMed1990

Soluble Fc gamma receptor III in human plasma originates from release by neutrophils.

FcRIII (the CD16-antigen), a low affinity receptor for IgG, is expressed by neutrophils, natural killer lymphocytes, and macrophages. We have developed a sensitive radioimmunoassay to quantify FcRIII. A soluble form of FcRIII was identified in human plasma. Immunoprecipitation of FcRIII from plasma showed that the plasma form of FcRIII has an identical electrophoretic mobility as the FcRIII expressed by neutrophils. Moreover, the plasma form of FcRIII exhibited the same polymorphism as does the neutrophil FcRIII. The neutrophil expresses the phosphatidylinositol-linked form of FcRIII, encoded by the gene FcRIII-1. Because it is not known whether this gene is also active in nonhematopoietic cells, we analyzed patients with an acquired clonal disorder of their hematopoietic cells, paroxysmal nocturnal hemoglobinuria (PNH). PNH patients appeared to have a strongly reduced expression of FcRIII on their neutrophils. The concentration of FcRIII in the plasma of these patients was also reduced, indicating that plasma FcRIII originates from neutrophils. A patient deficient in FcRIII-1 but with a normal expression of FcRIII-2 had no soluble FcRIII in her plasma, also indicating that plasma FcRIII originates from neutrophils. The electrophoretic mobility of the protein backbone of plasma FcRIII and FcRIII released by activated neutrophils was identical, whereas deglycosylated FcRIII obtained from a lysate of neutrophils migrated slower. This indicates that plasma FcRIII originates from activation-induced release by neutrophils. Stimulation of neutrophils or neutrophil cytoplasts (closed membrane vesicles filled with cytoplasm) with low concentrations of FMLP (10(-9)-10(-8) M) or phorbol myristate acetate (1-10 ng/ml) induced a dose-dependent release of FcRIII. The plasma concentration of FcRIII was relatively constant (range 40-280% of the mean). Soluble FcRIII was also detected in inflamed joint fluids of arthritis patients, suggesting that FcRIII is also released by activated neutrophils in vivo.

Antibodies, Monoclonal↗

PubMed1989

Proteolysis induces increased binding affinity of the monocyte type II FcR for human IgG.

Human monocytes express two types of IgG FcR, Fc gamma RI and Fc gamma RII. These can be assayed by using indicator E sensitized by human IgG (EA-human IgG) or mouse IgG1, (EA-mouse IgG1), respectively. On mouse macrophages, Fc gamma RI is sensitive to trypsin, whereas Fc gamma RII is trypsin resistant. We studied the effects of the proteolytic enzymes pronase and trypsin on human monocyte Fc gamma R. Neither enzyme caused a decrease in rosetting mediated by monocyte Fc gamma RI. Human Fc gamma RII is polymorphic, and monocytes interact either strongly or weakly with mouse IgG1. The interaction of low responder monocytes with mouse IgG1 was dramatically increased (to the level exhibited by high responder monocytes) by protease treatment. The effects of proteases on Fc gamma RII were investigated in more detail by using monocytes from which Fc gamma RI was selectively modulated by using immobilized immune complexes. Proteolysis of such modulated monocytes induced an increased interaction with EA-human IgG. Fc gamma RII appears to mediate this interaction. This conclusion is supported by the observation that after proteolysis, the Fc gamma RII-mediated binding of EA-mouse IgG1 becomes susceptible to inhibition by (monomeric) human IgG. To quantify the effect of proteolytic enzymes on Fc gamma RII, we performed binding studies with cell line K562, that expresses only Fc gamma RII. A significant increase in Ka of Fc gamma RII for dimeric human IgG complexes was observed when K562 cells were treated with protease. To elucidate the mechanism of this enhancement of Ka by proteolysis, we performed immunoprecipitation studies. Neither m.w., nor IEF pattern of Fc gamma RII were influenced by proteolysis. Moreover, the expression of Fc gamma RII was not affected by proteolysis as evidenced by immunofluorescence studies and Scatchard analysis, and neither were Fc gamma RI or Fc gamma RIII induced. We conclude that proteolysis increases the affinity of Fc gamma RII for human IgG, and speculate that such a proteolysis-induced change may also occur in vivo, e.g., at inflammatory sites.

Antibody Affinity↗

PubMed1989

The 40-kDa Fc gamma receptor (FcRII) on human neutrophils is essential for the IgG-induced respiratory burst and IgG-induced phagocytosis.

Neutrophils express two types of receptor for the Fc region of IgG, FcRII and FcRIII. Per neutrophil, 10,000 to 20,000 molecules of FcRII (40 kDa) and 100,000 to 200,000 molecules of FcRIII (50 to 80 kDa) are expressed. Via these receptors, neutrophils bind IgG complexes that contain more than one IgG molecule. This binding activates functional processes, such as the respiratory burst and phagocytosis. We studied the contribution of FcRII and FcRIII in the activation of these processes, using well-defined complexes (both large and small) in combination with mAb against FcRII and FcRIII. Small (dimeric) IgG complexes appeared to bind via FcRIII. However, binding to FcRIII alone, when FcRII is blocked by an anti-FcRII mAb, did not induce a respiratory burst. Induction of the respiratory burst by a large immune complex, such as Staphylococcus aureus Wood opsonized with IgG antibodies, was mediated by binding to FcRII, because it was blocked by an anti-FcRII mAb but not by an anti-FcRIII mAb. This indicates that these IgG-opsonized bacteria can cross-link FcRII and activate the cells without the need to adhere to the FcRIII. The respiratory burst induced by IgG-latex was not inhibited by an anti-FcRII mAb, because the avidity for FcRII of IgG-latex, a particle of the same size as a Staphylococcus but with a two to three times higher IgG content, is increased by its simultaneous binding to FcRIII. This enhanced avidity results in removal of anti-FcRII mAb from the FcRII by IgG-latex. This increased avidity of large complexes for FcRII, created by concurrent binding to FcRIII, is not necessary for activation of human neutrophils, because neutrophils from patients with paroxysmal nocturnal hemoglobinuria, with about 10% of the normal FcRIII expression, showed a normal metabolic response upon addition of IgG-latex. Phagocytosis of IgG-opsonized 14C-labeled S. aureus Wood was inhibited equally well by anti-FcRII mAb and by anti-FcRII in combination with anti-FcRIII mAb. Thus, FcRII is not only essential for the IgG-induced activation of the NADPH oxidase system, but also for the IgG-induced phagocytosis.

Antigens, Differentiation↗

PubMed1989

Binding characteristics of dimeric IgG subclass complexes to human neutrophils.

Immune complexes were prepared by incubation of human IgG paraproteins with F(ab')2 fragments of the mAb K35 against the kappa-L chain of human IgG. The composition of these complexes was analyzed by centrifugation over sucrose gradients, by gel filtration, by RIA with either IgG Sepharose or K35 Sepharose and by double-labeling studies. The results indicated that the complexes consist of saturated tetramers composed of two IgG molecules cross-linked by two F(ab')2 fragments of the mAb. These complexes were used to study the binding of the different IgG subclasses to human neutrophils at 4 degrees C. Human neutrophils bound IgG3 complexes approximately three times faster than IgG1 complexes. Binding of IgG2 or IgG4 dimers to the neutrophils was undetectable. The same number of IgG1 complexes and IgG3 complexes bound to the neutrophils, but considerable inter-donor variation was found (mean number of Fc gamma R per neutrophil: 190,000, range 120,000 to 400,000). The Ka for the binding of IgG1 complexes to neutrophils (median 11 x 10(7) M-1) was lower than the Ka for the binding of IgG3 complexes (median 47 x 10(7) M-1). Competition studies between labeled IgG1 complexes or IgG3 complexes and unlabeled complexes showed that the Fc gamma R of human neutrophils do not display an IgG subclass specificity. Incubation of neutrophils with a mAb against the FcRIII completely blocked the binding of IgG1 complexes and IgG3 complexes. Incubation with a mAb against the FcRII reduced the affinity of the complexes for the neutrophils but had no effect on the maximum number of complexes bound. This indicates that one complex may bind simultaneously to one FcRIII and to one FcRII.

Animals↗

PubMed1988

The PI-linked receptor FcRIII is released on stimulation of neutrophils.

Human phagocytic cells express receptors for the constant (Fc) region of immunoglobulin G. Neutrophils carry Fc receptor II (FcRII; CDw32) and FcRIII (CD16) which both bind IgG-containing immune complexes, leading to phagocytosis of the complex and activation of the neutrophil. We find that patients with paroxysmal nocturnal haemoglobinuria (PNH) have only about 10% of the normal levels of FcRIII on their neutrophils, whereas the expression of FcRII is unaffected. We show that FcRIII is a phosphatidyl inositol (PI)-anchored protein in neutrophils. Analysis of FcRIII expression in cells of PNH patients, known to be deficient in PI-linked proteins, suggests FcRIII is not PI-linked in monocytes. We find that the synthesis of FcRIII in neutrophils from PNH patients appears normal, indicating that the defect lies in the PI linkage. This lipid linkage of the receptor on neutrophils suggests that its release may be important for its function, and indeed FcRIII release was observed on stimulation of neutrophils by an inflammatory bacterial peptide (f-Met-Leu-Phe), suggesting a role for FcRIII shedding in inflammatory reactions. Activation of the PNH neutrophils with IgG-coated latex beads appeared normal (although binding of dimer IgG complexes was reduced), indicating that FcRII, rather than FcRIII, is involved in neutrophil stimulation.

Hemoglobinuria, Paroxysmal↗

PubMedDate not supplied

An extended HLA-DQ-DR haplotype rather than DRB1 alone contributes to RA predisposition.

In the present study, we tested our hypothesis on the role of a DQ-DR haplotype in rheumatoid arthritis (RA) predisposition. Using two groups of patients and controls, one from The Netherlands and one from Switzerland, we found that DQA1*0301-homozygous and DQA1*0301//DQA1*0101/04-heterozygous individuals are highly predisposed to RA in both populations, while DQA1*0101/04-homozygous are not. The DQA1*0301-DRB1*0403/06/07 and DQA1*0301-DRB1*0901 haplotypes are not associated with RA by themselves but strongly increase the risk of developing disease in DQA1*0301- and DQA1*0101/04-heterozygous. DRB1 alleles carrying the motif DERAA in their third hypervariable region, i.e., *0103, *0402, *1102, *1103, *1301, and *1302, provide a long-lasting protection against RA in DQA1*0101/04- but not in DQA1*0301-positive individuals. These data show that considering both DQ and DR gives a better distinction between patients and controls than the shared epitope hypothesis.

Arthritis, Rheumatoid↗

PubMedDate not supplied

The accuracy of diagnosing neuropsychiatric systemic lupus erythematosus in a series of 49 hospitalized patients.

OBJECTIVE: Neuropsychiatric manifestations in patients with systemic lupus erythematosus (SLE) originate from immune-mediated disease (primary neuropsychiatric SLE) or from other pathogenetic mechanisms indirectly related to SLE (secondary neuropsychiatric SLE). The objective of this study is to describe the clinical practice of diagnosing NP-SLE and to assess how often the diagnosis of primary NP-SLE is changed to secondary NP-SLE and vice versa during the follow-up period in a large series of hospitalized SLE patients. MATERIALS AND METHODS: Data was collected by means of retrospective evaluation of the charts of 191 SLE patients admitted during the period 1986 to 1995. RESULTS: Of 191 admitted SLE patients, 49 had developed neuropsychiatric signs and symptoms. At admission 30 patients were classified as having primary NP-SLE and 19 patients secondary NP-SLE. During follow-up the diagnosis was changed to primary NP-SLE in 2 patients initially diagnosed as suffering from secondary NP-SLE, and in two patients from primary to secondary NP-SLE. Seizures, cognitive deterioration, psychosis and organic brain syndrome were the most frequent manifestations in primary NP-SLE, whereas in secondary NP-SLE headache, seizures, paresis and organic brain syndrome prevailed. 47% of the primary NP-SLE patients were re-admitted to hospital because of recurrent neuropsychiatric manifestations within 4.5 years, while 10% died due to primary NP-SLE. The prognosis of secondary NP-SLE was dependent on the diagnosis. CONCLUSION: In the large majority of patients the initial diagnosis of primary or secondary NP-SLE made upon their admittance to hospital is confirmed during the long-term follow-up.

Adolescent↗

PubMedDate not supplied

The effect of promoter strength in adenoviral vectors in hyperplastic synovium.

OBJECTIVES: To compare the activity of the CytoMegaloVirus promoter (CMV) and the Major Late promoter (MLP) in synoviocytes in vitro and in vivo. To determine the phenotype of infected cells and the induction of inflammation. To investigate the effects of the cytomegalovirus (CMV) or major late (MLP) promoter on adenovirus-mediated reporter gene transduction of synoviocytes in vitro and in vivo. METHODS: After infection with adenoviral vectors harboring CMV- and MLP-driven luciferase and lacZ genes, gene expression was examined in cultured synoviocytes and in the synovium of rhesus monkeys with collagen-induced arthritis. Immunohistochemical staining for the macrophage-marker CD68 and lacZ expression was performed. Inflammation was scored in the synovial membrane of injected and non-injected joints. RESULTS: CMV-driven reporter gene expression was found to be 6 to 10 times higher than MLP-driven gene expression in both cultured synoviocytes and monkey synovium. Both CD68 positive and CD68 negative cells were lacZ positive. Inflammation in joints injected with CMV-driven adenoviral vectors was not higher than that in MLP-driven adenoviral vectors- or non-injected joints. CONCLUSION: These experiments show that the CMV promoter induces higher gene expression in synoviocytes than the MLP promoter. Both fibroblast-like and macrophage-like synoviocytes can be infected with adenoviral vectors. No deleterious effects of the CMV-promoter driven adenoviral vectors were observed.

Adenoviridae↗

PubMedDate not supplied

No therapeutic effect of plasmin antagonist tranexamic acid in rheumatoid arthritis. A double-blind placebo-controlled pilot study.

OBJECTIVE: In the present study, the effects of plasmin antagonist tranexamic acid (TEA) on urinary pyridinoline excretion rates were investigated in rheumatoid arthritis (RA) patients. METHODS: The study was set up as a double-blind placebo-controlled pilot study. Ten patients received tranexamic acid and 9 received placebo for 12 weeks. Urinary excretion rates of hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) were used as molecular markers of articular cartilage and bone degradation. In addition, clinical parameters of disease activity were assessed and CRP levels were measured. RESULTS: Treatment with TEA did not reduce pyridinoline excretion, nor was any effect observed on clinical parameters of disease activity or on CRP levels. CONCLUSION: The results of the present pilot study show no beneficial effect of TEA as adjuvant therapy in RA patients with respect to joint destruction or disease activity.

Amino Acids↗

PubMedDate not supplied

Active MMPs captured by alpha 2 macroglobulin as a marker of disease activity in rheumatoid arthritis.

OBJECTIVE: The aim of the present study was to analyze alpha 2 Macroglobulin/MMP (alpha 2M/MMP) complex formation and to investigate whether MMP activity in alpha 2M/MMP complexes in serum can be used as a disease marker in rheumatoid arthritis (RA). METHODS: High and low molecular weight (H/LMW) substrates and inhibitors and size exclusion were used to analyze alpha 2M/MMP complex formation. LMW fluorogenic substrates were used to quantify the level of MMPs in alpha 2M/MMP complexes in the serum of RA patients and healthy controls. RESULTS: Active MMPs were fully inhibited by LMW inhibitor BB94 in the presence of alpha 2M, whereas no inhibition was achieved by HMW inhibitor TIMP-1. Size exclusion analysis showed alpha 2M/MMP complex formation in buffer and in normal plasma spiked with activated MMPs, which indicated alpha 2M/MMP complex formation in the systemic circulation. MMP activity in alpha 2M/MMP complexes in the serum of RA patients was significantly higher than in the serum of healthy controls (P < 0.001). MMP activity levels in the serum of RA patients were correlated with ESR (r = 0.72, P < 0.001). CONCLUSION: In the systemic circulation of RA patients, active MMPs form complexes with alpha 2M and can be detected using LMW fluorogenic substrates. MMP activity measurements in serum allow discrimination between RA patients and healthy controls and provide a new tool for the assessment of the disease process in RA.

Adult↗

PubMedDate not supplied

The Leiden Early Arthritis Clinic.

In 1993 a special Early Arthritis Clinic (EAC) was established at the Department of Rheumatology of the Leiden University Medical Center in order to detect and treat inflammatory disorders early in the disease state, especially early rheumatoid arthritis. Patients with confirmed arthritis of recent onset (less than 2 years) were included by rheumatologists and trained research nurses. Parameters of first and follow-up visits (3, 6 and 9 months and yearly) that were entered in the EAC-database include the medical history, physical-diagnostic examination, laboratory tests, questionnaires, radiographic joint scores and diagnosis. This database enables us to conduct research on arthritis, with an emphasis on rheumatoid arthritis, in many ways. Physicians and basic scientists have studied cellular immunology and genetic, environmental and clinical risk factors in order to determine the pathophysiologic mechanisms of inflammatory arthritis. The present article is a review on reports published from the EAC. Over the past ten years, these reports have been highly relevant for both daily clinical practice and research. Present and planned future studies, as described in this article, reconfirm the importance of an EAC framework to ensure that research continues on this disease in the Leiden EAC area.

Ambulatory Care Facilities↗